Department of Surgical Oncology-Unit 444, The University of Texas M D Anderson Cancer Center, 1400 Holcombe Boulevard, Suite 12.2016, Houston, TX 77030, USA.
J Gastrointest Surg. 2011 Mar;15(3):416-9. doi: 10.1007/s11605-011-1429-6. Epub 2011 Feb 8.
The gold-standard treatment for colorectal liver metastases (CLM) is liver resection. Advances in staging, surgical technique, perioperative care and systemic chemotherapy have contributed to steady improvement in oncologic outcomes for patients following surgery in this subset of patients with stage IV colorectal cancer. The limits of resection continue to expand to include patients with more, larger and bilateral CLM, yet outcomes continue to improve with 5-year overall survival exceeding 50% following resection. Chemotherapy is an important element of treatment for patients with CLM, and chemotherapy can be combined safely with surgery to improve outcomes further.
Tailored approaches to patients include major (anatomic) resection, minor (wedge) resection, liver volumetry, and preoperative enhancement of the volume and function of the planned future remnant liver using portal vein embolization.
Assessment of response to chemotherapy, analysis of liver remnant volume changes following portal vein embolization, and consideration of the surgical recovery following multistage surgical resection of bilateral CLM enable remarkable survival even among properly selected patients with extensive disease.
Until laboratory, pathologic, biologic, or genetic studies can define which patients will benefit most from surgical and other treatments, careful application of proven diagnostic and therapeutic approaches to patients with advanced disease will continue to allow surgeons to direct tailored, patient-centered treatment as part of a multidisciplinary team.
结直肠肝转移(CLM)的金标准治疗方法是肝切除术。分期、手术技术、围手术期护理和系统化疗方面的进步,使接受手术治疗的这部分 IV 期结直肠癌患者的肿瘤学结果得到了稳步改善。肝切除术的适应证范围不断扩大,包括更多、更大和双侧 CLM 的患者,但手术切除后 5 年总生存率仍超过 50%,这一结果仍在持续改善。化疗是 CLM 患者治疗的重要组成部分,化疗可以与手术安全结合使用,以进一步提高疗效。
为患者制定的方法包括解剖性肝切除术、楔形肝切除术、肝脏体积测量术,以及通过门静脉栓塞术术前增强计划未来剩余肝脏的体积和功能。
评估化疗反应、分析门静脉栓塞术后肝残留体积变化,以及考虑双侧 CLM 多阶段手术切除后的手术恢复情况,即使在选择合适的广泛疾病患者中,也能获得显著的生存获益。
在实验室、病理、生物学或遗传学研究能够明确哪些患者将从手术和其他治疗中获益最多之前,对晚期疾病患者仔细应用经过验证的诊断和治疗方法,将继续使外科医生能够作为多学科团队的一部分,为患者提供个体化、以患者为中心的治疗。